Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.
A large national study in Denmark following nearly 1,900 patients over almost a decade found that a minimally invasive ...
At the Texas A&M University Large Animal Teaching Hospital (LATH), a horse had a 30-lb tumor, larger than a basketball, ...
The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell ...
SAN FRANCISCO -- Adjuvant durvalumab (Imfinzi) and tremelimumab (Imjudo) improved disease-free survival (DFS) in a phase III ...
(HealthDay News) — Adult patients with cancer who experience a new-onset mental health disorder (MHD) have an increased risk for death, according to a study published online Feb. 23 in Cancer.
A large national study in Denmark following nearly 1,900 patients over almost a decade has found that a minimally invasive ...
In this observational study, researchers aimed to assess real-world use of relugolix among prostate cancer patients.
Long-term morbidity varies by chemotherapy regimen, with higher odds of worse renal impairment seen with EPx4 vs BEPx3.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results